ArticleBMC cancer2025
Evaluation of performance indicators of a national breast cancer screening program in Casablanca, Morocco.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ONMORE-Africa: diagnosing and building real-world oncology studies in Morocco and Africa.ESMO real world data and digital oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMorocco's national breast cancer screening program (NBCSP) was launched in 2010 in response to rising breast cancer incidence. The program comprises clinical breast examination (CBE) and diagnostic mammography and aims to improve early diagnosis and breast cancer management. This study evaluated key performance indicators of the NBCSP for the Casablanca-Settat region from 2018 to 2021.
methodsAggregated regional data on screening and diagnostic activities under the NBCSP were extracted from a health information system. Annual screening coverage, participation, CBE-positivity, and breast cancer detection rates for the region were then calculated. Screening numbers and CBE positivity rates were compared by year and sub-region using one-way ANOVA and Bonferroni multiple-comparison tests. Trends in breast cancer screenings were also compared using Pearson's correlation coefficients and statistical trend tests.
resultsFrom 2018 to 2021, a total of 846,692 women in the Casablanca-Settat region were screened under the NBCSP, and 21,476 referred for a positive CBE to a designated secondary referral center for diagnostic mammography. Annual screening coverage rates of eligible women ranged from 10.4 to 28.8% during the study period. Only two out of nine administrative sub-regions in Casablanca-Settat achieved a desired 40% screening coverage threshold. Overall, annual participation among the target population from 2018 to 2021 decreased by 44.8%. Annual CBE positivity rates remained stable between 2.2 and 2.7%, though notable variations were observed at the sub-regional level. Over one-third (36.4%, n = 7,808) of CBE-positive women sought consultations at designated secondary referral centers in the region. Compliance to further diagnostic testing at these centers increased overtime, from 24.2% in 2018 to 61.9% in 2021. Breast cancer detection rates in the region from 2018 to 2021 were: 0.7, 0.8, 1.0, to 1.1 per 1000 women screened, respectively.
conclusionsThe NBCSP fell short of achieving its desired performance benchmarks in the Casablanca-Settat region from 2018 to 2021, notably in screening coverage, participation, and CBE positivity rates. Annual breast cancer detection rates under the program also remained low. Additional interventions are needed to increase screening participation, standardize CBE training, and establish linkages between health facilities to limit the underestimation of breast cancer under the NBCSP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.